CMMB (chemomab.com) Forward P/S Multiple

The shortage of solutions for fibro-inflammatory pathologies guarantees colossal demand, as confirmed by the forward P/S valuation history for Chemomab Therapeutics (CMMB). The value of describes the current level of market expectations. Chemomab Therapeutics (CMMB) revenues rely on the commercialization of CM-101 antibodies against systemic sclerosis. The innovative ecosystem aims to stop tissue scarring in the lungs and liver, creating a unique opportunity for patient recovery.

Chemomab Therapeutics Ltd - CMMB Forward P/S Multiple (period 07/04/2022 - 11/15/2026)

Summary analytical data breakdowns for Chemomab Therapeutics Ltd. (CMMB)

- market price and analyst price targets:

Price Chart Chemomab Therapeutics Ltd|CMMB - Forecast Levels Chart

- business market valuation indicators:

Market Capitalization Chemomab Therapeutics Ltd|CMMB - Value Adjusted for Debt and Cash

- issuer book value statistics:

Book Value per Share Chemomab Therapeutics|CMMB - Book Capitalization|Market Value to Book Value Ratio chemomab.com|CMMB - Aggregate Asset Value

- debt and solvency information:

- financial results and valuation multiples details:

CMMB - Company Net Income|Expected Profit Chemomab Therapeutics|CMMB - Price to Earnings Ratio|Future Price to Earnings Chemomab Therapeutics Ltd.|CMMB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Chemomab Therapeutics Ltd|CMMB - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Chemomab Therapeutics|CMMB - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth chemomab.com|CMMB - Earnings per share growth in current year|Expected earnings per share growth for next year Chemomab Therapeutics

- total revenue and sales volume data:

CMMB - Company Sales Revenue|Company Future Sales Volume Chemomab Therapeutics Ltd.|CMMB - Market Cap to Sales Volume|Forward P/S Multiple Chemomab Therapeutics Ltd|CMMB - Revenue Dynamics YoY (Last Twelve Months)

Fundamental company analysis:Chemomab Therapeutics Ltd. CMMB

For long-term asset screening, it is critical to correlate current market value with potential cash flows to avoid overpaying for future growth. This indicator compares the market capitalization of Chemomab Therapeutics (CMMB) with projected revenue, assessing the value of future earnings within the context of the CM-101 drug development, which allows the company's expected P/S ratio to determine the risk of overvaluation for this biotech business.

Competitors of Chemomab Therapeutics (CMMB)

Price-to-Projected Revenue Ratio Vertex VRTX|ALNY (Alnylam Inc.) - Future Price to Revenue|Insmed Incorporated - Forward P/S Multiple|Forward Price to Sales UTHR (United Therapeutics)|BMRN: Forward P/S Multiple|BridgeBio Pharma (BBIO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio bgm.ltd|COGT: Forward Price to Sales|Price-to-Projected Revenue Ratio xerispharma.com (XERS)|Forward Price-to-Revenue Multiple Keros Therapeutics KROS|Forward P/S Multiple ARCT (arcturusrx.com)|Forward P/S Multiple Eton Pharmaceuticals, Inc. ETON|KMDA - Price-to-Projected Revenue Ratio|Future Price to Revenue FULC|ABEO: Forward P/S Multiple|Market Cap to Future Revenue Ratio Mereo BioPharma Group PLC (MREO)|Forward Price-to-Revenue Multiple PLX|Pliant Therapeutics (PLRX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Applied Therapeutics (APLT)|Rein Therapeutics Inc - Market Cap to Projected Revenue|Forward P/S Multiple GELS (Gelteq)|Forward Price to Sales AYTU|SRx Health - Forward P/S Multiple|Market Cap to Expected Sales Ratio Polyrizon Limited PLRZ|AEZS: Forward P/S Multiple|CYTH: Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple INZY|RPHM: Forward Price to Sales|Forward Price-to-Revenue Multiple CSCI (COSCIENS Biopharma)